Tandem Diabetes met Wall Street's revenue and profit expectations in Q2, reporting revenue of $254.6 million versus analyst estimates of $253.8 million. However, the market responded negatively, likely reflecting investor caution around US pump shipment pace and the company's business model transition. Management highlighted stronger pump shipment growth internationally and early traction from its new pharmacy channel in the US. CEO John Sheridan emphasised operational efficiencies and expanded access to technology contributed to improved margins. The company reconfirmed its full-year revenue guidance of $1.08 billion at the midpoint. Operating margin improved to -5.4%, up from -21.5% in the same quarter last year. Analyst questions focused on pharmacy transition progress, type 2 diabetes retention trends, and the timeline for Mobi tubeless FDA clearance and launch.

Tandem Diabetes Care met Wall Street's revenue expectations in Q2 2026, reporting sales of $254.6 million, up 5.8% year on year. The diabetes technology company's GAAP loss of $0.31 per share aligned with analyst estimates. The company reaffirmed its full-year revenue guidance of $1.08 billion at the midpoint, close to analyst forecasts. Adjusted EBITDA of $6.42 million beat expectations by 82.2%, with a 2.5% margin. Operating margin improved to -5.4%, up from -21.5% in the same quarter last year. However, free cash flow was -$38.67 million, compared to -$15.7 million in Q2 2025. Analysts expect revenue to grow 9.3% over the next 12 months. Over the past five years, Tandem Diabetes has grown sales at an 11.5% compounded annual growth rate.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) given consensus rating of "Hold" by analysts. July 30, 2026 Key points. * Analysts rate Tandem Diabetes Care "Hold" overall: Of 22 firms, 11 recommend holding, nine recommend buying, one strongly recommends buying, and one recommends selling. The average 12-month price target is $28.73. * Recent analyst actions were mixed, with TD Cowen raising its target to $28 while Bank of America and Citigroup cut targets to $25 and $17, respectively. * Tandem reported better-than-expected quarterly results, including an adjusted loss of $0.30 per share versus the $0.46 expected and revenue of $247.2 million, up 5.5% year over year. Shares opened at $18.59, while several institutional investors recently established or expanded positions. * Interested in Tandem Diabetes Care? Here are five stocks we like better. Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Get Free Report) has been assigned a consensus recommendation of "Hold" from the twenty-two research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $28.7250. TNDM has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft started coverage on shares of Tandem Diabetes Care in a research note on Tuesday, June 23rd. They issued a "hold" rating and a $15.50 target price for the company. TD Cowen restated a "buy" rating and set a $28.00 price target (up from $25.00) on shares of Tandem Diabetes Care in a research note on Monday, April 20th. Bank of America decreased their price target on shares of Tandem Diabetes Care from $35.00 to $25.00 and set a "neutral" rating for the company in a report on Monday, May 18th. Benchmark assumed coverage on shares of Tandem Diabetes Care in a research note on Monday, May 11th. They set a "hold" rating for the company. Finally, Citigroup reissued a "neutral" rating and set a $17.00 price objective (down from $22.00) on shares of Tandem Diabetes Care in a report on Thursday, May 28th. Institutional trading of Tandem Diabetes Care. A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Freestone Grove Partners LP acquired a new position in shares of Tandem Diabetes Care in the third quarter valued at about $22,706,000. First Light Asset Management LLC purchased a new position in shares of Tandem Diabetes Care in the fourth quarter worth about $23,947,000. BNP Paribas Financial Markets lifted its holdings in shares of Tandem Diabetes Care by 468.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,248,481 shares of the medical device company's stock worth $27,442,000 after purchasing an additional 1,028,866 shares during the period. Marshall Wace LLP acquired a new stake in shares of Tandem Diabetes Care during the fourth quarter worth about $19,244,000. Finally, Defilade Capital Management L.P. purchased a new stake in Tandem Diabetes Care in the first quarter valued at approximately $14,606,000. Tandem Diabetes Care trading up 4.7%. Tandem Diabetes Care stock opened at $18.59 on Thursday. The stock has a 50-day moving average of $16.36 and a two-hundred day moving average of $18.92. The company has a debt-to-equity ratio of 4.54, a quick ratio of 3.07 and a current ratio of 3.58. Tandem Diabetes Care has a one year low of $9.98 and a one year high of $29.65. The stock has a market cap of $1.27 billion, a PE ratio of -13.28 and a beta of 1.58. Discover more Cryptocurrency News investment Stock Screener Tool Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.16. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The business had revenue of $247.22 million for the quarter, compared to analyst estimates of $240.41 million. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. The company's revenue was up 5.5% on a year-over-year basis. On average, research analysts anticipate that Tandem Diabetes Care will post -0.72 EPS for the current fiscal year. About Tandem Diabetes Care. Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim(R) Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities. The company's flagship offering, the t:slim X2(R) Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Tandem Diabetes Care, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tandem Diabetes Care wasn't on the list. While Tandem Diabetes Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.